

# Prognostic and Predictive Potential of CCL5 Expression for Muscle Invasive Bladder Cancer Patients

Cedric Smolka <sup>1,2,†</sup>, Markus Eckstein <sup>1,3,4,†</sup>, Rudolf Jung <sup>1</sup>, Verena Lieb <sup>2,3</sup>, Danijel Sikic <sup>2,3,4</sup>, Robert Stöhr <sup>1,3,4</sup>, Veronika Bahlinger <sup>1</sup>, Simone Bertz <sup>1,3</sup>, Astrid Kehlen <sup>5</sup>, Arndt Hartmann <sup>1,3,4</sup>, Bernd Wullich <sup>2,3,4</sup>, Helge Taubert <sup>2,3,4,\*;‡</sup> and Sven Wach <sup>2,3,4,‡</sup>

**Table S1.** CCL5 expression in TCs and in ICs of MIBC patients.

	N	CCL5 negative (in %)	CCL5 positive (in %)
Tumor cells (TCs)	175	100 (57.1)	75 (42.9)
Immune cells (ICs)	175	52 (29.7)	123 (70.3)

**Table S2.** Spearman's bivariate correlation between CCL5 staining in TCs or ICs and clinicopathological/molecular parameters in MIBC patients.

Parameter	CCL5 in TCs		CCL5 in ICs	
<b>Gender</b>	<i>r<sub>s</sub></i>	0.011	<i>r<sub>s</sub></i>	0.035
	P	0.884	P	0.642
<b>Age at cystectomy</b>	<i>r<sub>s</sub></i>	0.067	<i>r<sub>s</sub></i>	0.008
	P	0.375	P	0.921
<b>pT</b>	<i>r<sub>s</sub></i>	0.019	<i>r<sub>s</sub></i>	-0.104
	P	0.806	P	0.170
<b>pN</b>	<i>r<sub>s</sub></i>	0.159	<i>r<sub>s</sub></i>	-0.036
	P	<b>0.036*</b>	P	0.633
<b>OS</b>	<i>r<sub>s</sub></i>	-0.141	<i>r<sub>s</sub></i>	-0.068
	P	0.062	P	0.371
<b>DSS</b>	<i>r<sub>s</sub></i>	-0.134	<i>r<sub>s</sub></i>	0.152
	P	0.078	P	<b>0.045*</b>
<b>Survival time</b>	<i>r<sub>s</sub></i>	-.195	<i>r<sub>s</sub></i>	0.234
	P	<b>0.010*</b>	P	<b>0.002**</b>
<b>time to recurrence</b>	<i>r<sub>s</sub></i>	-0.163	<i>r<sub>s</sub></i>	0.257
	P	<b>0.031*</b>	P	<b>0.001**</b>
<b>RFS</b>	<i>r<sub>s</sub></i>	-0.134	<i>r<sub>s</sub></i>	0.152
	P	0.078	P	<b>0.045*</b>
<b>CCL5 in ICs/TCs</b>	<i>r<sub>s</sub></i>	0.184	<i>r<sub>s</sub></i>	0.184
	P	<b>0.015*</b>	P	<b>0.015*</b>
<b>Chemotherapy</b>	<i>r<sub>s</sub></i>	0.015	<i>r<sub>s</sub></i>	-0.006
	P	0.840	P	0.932
<b>molecular subtypes</b>	<i>r<sub>s</sub></i>	-0.070	<i>r<sub>s</sub></i>	-0.015
	P	0.359	P	0.844
<b>TILs</b>	<i>r<sub>s</sub></i>	-0.023	<i>r<sub>s</sub></i>	0.368
	P	0.763	P	<b>&lt;0.001**</b>
<b>CD3</b>	<i>r<sub>s</sub></i>	-0.012	<i>r<sub>s</sub></i>	0.301
	P	0.877	P	<b>&lt;0.001**</b>
<b>CD8</b>	<i>r<sub>s</sub></i>	-0.010	<i>r<sub>s</sub></i>	0.348
	P	0.893	P	<b>&lt;0.001**</b>
<b>CD56</b>	<i>r<sub>s</sub></i>	0.043	<i>r<sub>s</sub></i>	0.351
	P	0.569	P	<b>&lt;0.001**</b>
<b>CXCL9</b>	<i>r<sub>s</sub></i>	0.009	<i>r<sub>s</sub></i>	0.394
	P	0.911	P	<b>&lt;0.001**</b>

Characterization of TILs, CD3, CD8, CD56 and CXCL9 have been described previously [9]. Significant values are marked in bold. *r<sub>s</sub>*=correlation coefficient, P=P-value (2-sided), \*P<0.05, \*\*P < 0.01.